DOYLESTOWN, Pa., May 1 /PRNewswire-FirstCall/ -- The Quigley Corporation today announced it has retained CRT Capital Group LLC as its financial advisor and investment banker.
CRT will provide Quigley with financial advisory services and assist the Company in developing and evaluating strategic and capital market alternatives in the ordinary course of its ongoing business planning. In addition, CRT will serve as a market maker in Quigley’s common stock.
Guy J. Quigley, Chairman, President and Chief Executive Officer, said, “We are very pleased to have a high-caliber firm like CRT come on board. We believe an experienced financial advisor and investment banker will benefit, as well as complement, our internal efforts to enhance long-term shareholder value.”
About CRT Capital Group LLC
CRT Capital Group LLC, www.crtllc.com, is a full-service investment banking and institutional securities firm that provides capital markets, research and advisory services to its corporate and institutional clients. Based in Stamford, Connecticut, CRT’s more than 90 professionals have significant experience assisting middle-market companies and their investors with a wide range of financial services and products in both public and private capital markets.
About The Quigley Corporation
The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.
Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company’s actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
CONTACT: Albert Piechotta Director of Corporate Communications (215)345-0919 Carl Hymans G.S. Schwartz & Co. (212)725-4500 carlh@schwartz.com
The Quigley Corporation
CONTACT: Albert Piechotta, Director of Corporate Communications,+1-215-345-0919; Carl Hymans, G.S. Schwartz & Co., +1-212-725-4500,carlh@schwartz.com
